FEDERAL · 2026-16727

Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product

SEP 16, 2026Other rules

Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product. Issued by Health and Human Services Department, Food and Drug Administration.

What changes

Other rules

Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product

Timeline

Published August 17, 2026
Takes effect September 16, 2026

Official text

Source: U.S. Federal Register (public domain) · View the official text ↗. The effective date comes from the official document; confirm on the source.